fosamprenavir has been researched along with amprenavir in 41 studies
| Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (amprenavir) | Trials (amprenavir) | Recent Studies (post-2010) (amprenavir) |
|---|---|---|---|---|---|
| 174 | 55 | 37 | 555 | 91 | 94 |
| Protein | Taxonomy | fosamprenavir (IC50) | amprenavir (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.027 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 0.0026 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.013 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0558 | |
| Thromboxane-A synthase | Homo sapiens (human) | 6.727 | |
| Protease | Human immunodeficiency virus 1 | 0.1553 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 32 (78.05) | 29.6817 |
| 2010's | 6 (14.63) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gatell, JM | 1 |
| Bye, C; Falcoz, C; Fuder, H; Hardman, TC; Jenkins, JM; Kenney, KB; Prince, WT; Studenberg, S | 1 |
| Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB | 1 |
| Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J | 1 |
| Baker, CT; Furfine, ES; Hale, MR; Reynolds, DJ; Salisbury, JA; Searle, AD; Spaltenstein, A; Studenberg, SD; Todd, D; Tung, RD | 1 |
| Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Honda, Y; Izawa, K; Katayama, S; Kishibata, N; Kojima, M; Suzuki, T | 1 |
| Baker, KL; Ford, SL; Lou, Y; Stein, DS; Wire, MB | 1 |
| Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN | 1 |
| Arvieux, C; Tribut, O | 1 |
| Elston, R; Kleinkauf, N; Schürmann, D; Suttorp, N; Wünsche, T; Xu, F | 1 |
| Bhatti, L; Farthing, C; Khanlou, H | 1 |
| Shelton, MJ; Studenberg, S; Wire, MB | 1 |
| Baker, KL; Berrey, MM; Jones, LS; Lou, Y; Shelton, MJ; Thomas, GJ; Wire, MB | 1 |
| Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G | 1 |
| Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M | 1 |
| Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB | 1 |
| Augustijns, P; Brouwers, J; Tack, J | 2 |
| Ballow, CH; Borland, J; Lewis, EW; Lin, J; Lou, Y; Shelton, MJ; Wire, MB; Yuen, G | 1 |
| Banik, N; Breske, A; Kruse, G; Kurowski, M; Mazur, D; Richter, H; Stocker, H; Walli, RK | 1 |
| Bastiani, E; Benedetti, F; Berti, F; Campaner, P; Donadel, E; Montagna, M; Regazzi, M; Rinaldi, S; Savoini, A; Venturini, R | 1 |
| Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C | 1 |
| Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
| Delgado, O; Murillas, J; Riera, M; Ventayol, P | 1 |
| Bigelow, GE; Cao, YJ; Causon, RC; Fuchs, EJ; Hendrix, CW; Lancaster, CT; Lou, Y; Martinez, E; McCabe, S; Radebaugh, C; Smith, PF; Wire, MB | 1 |
| Anderson, PL; Clay, PG; Glaros, AG; McRae, M | 1 |
| Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD | 1 |
| Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A | 1 |
| Browning, MR; Drexler, DM; Morgan, DG; Olah, TV | 1 |
| Borland, J; Chen, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T | 1 |
| Barbour, AM; Gibiansky, L; Wire, MB | 1 |
| Augustijns, P; Braeckmans, M; Brouwers, J; Masuy, I; Servais, C; Tack, J | 1 |
| Bauer-Brandl, A; Brandl, M; Christiansen, JJ; Eriksen, JB; Rautio, J; Ruponen, M | 1 |
| Blaine-Sauer, S; Johnston, N; Samuels, TL; Yan, K | 1 |
6 review(s) available for fosamprenavir and amprenavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
From amprenavir to GW433908.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Furans; HIV Infections; Humans; Organophosphates; Prodrugs; Sulfonamides | 2001 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides | 2005 |
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Topics: Adult; Carbamates; Drug Interactions; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Absorption; Organophosphates; Prodrugs; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution | 2006 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
17 trial(s) available for fosamprenavir and amprenavir
| Article | Year |
|---|---|
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
Topics: Adolescent; Adult; Area Under Curve; Capsules; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Fasting; Food-Drug Interactions; Furans; Health; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Sulfonamides; Suspensions; Tablets | 2002 |
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides | 2004 |
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cholesterol; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Linear Models; Male; Middle Aged; Organophosphates; Oxazines; Prodrugs; Ritonavir; Sulfonamides; Triglycerides | 2004 |
Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Magnesium Hydroxide; Organophosphates; Ranitidine; Sulfonamides | 2005 |
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome | 2005 |
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
Topics: Adult; Area Under Curve; Carbamates; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2007 |
Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
Topics: Administration, Oral; Adult; Carbamates; Cross-Over Studies; Duodenum; Fasting; Feasibility Studies; Female; Food-Drug Interactions; Furans; Gastric Juice; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Secretions; Male; Organophosphates; Postprandial Period; Solubility; Sulfonamides; Tablets | 2007 |
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome | 2007 |
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
Topics: Adenine; Anti-Retroviral Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Organophosphates; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; Humans; Male; Methadone; Narcotics; Organophosphates; Prodrugs; Ritonavir; Stereoisomerism; Sulfonamides | 2008 |
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Prodrugs; Pyridines; Ritonavir; Sulfonamides | 2009 |
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2010 |
Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
Topics: Adult; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Interactions; Female; Furans; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Organophosphates; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides | 2014 |
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides | 2014 |
The influence of gastric motility on the intraluminal behavior of fosamprenavir.
Topics: Adult; Carbamates; Cross-Over Studies; Digestion; Duodenum; Female; Furans; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Male; Middle Aged; Organophosphates; Stomach; Sulfonamides; Young Adult | 2020 |
18 other study(ies) available for fosamprenavir and amprenavir
| Article | Year |
|---|---|
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Phase III trials for new PI.
Topics: Antiretroviral Therapy, Highly Active; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Randomized Controlled Trials as Topic; Sulfonamides | 2001 |
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides | 2002 |
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
Topics: Animals; Biological Availability; Biotransformation; Caco-2 Cells; Carbamates; Dogs; Furans; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Mass Spectrometry; Organophosphates; Prodrugs; Rats; Rats, Wistar; Sulfonamides | 2004 |
New approaches to the industrial synthesis of HIV protease inhibitors.
Topics: Carbamates; Furans; HIV Protease Inhibitors; Molecular Conformation; Molecular Structure; Organophosphates; Sulfonamides | 2004 |
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mutation; Organophosphates; Prodrugs; Sulfonamides | 2006 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia | 2006 |
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Combinations; Esomeprazole; Female; Furans; Headache; Humans; Male; Middle Aged; Nausea; Organophosphates; Ritonavir; Sulfonamides | 2006 |
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome | 2006 |
In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
Topics: Alkaline Phosphatase; Biological Transport; Caco-2 Cells; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Intestinal Absorption; Intestinal Secretions; Organophosphates; Permeability; Phosphates; Phosphorylation; Prodrugs; Solubility; Sulfonamides | 2007 |
Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir.
Topics: Adult; Animals; Anti-HIV Agents; Antibodies; Carbamates; Chromatography, High Pressure Liquid; Cross Reactions; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Furans; Humans; Immune Sera; Molecular Structure; Organophosphates; Ovalbumin; Rabbits; Reproducibility of Results; Serum Albumin, Bovine; Sulfonamides; Vaccination | 2007 |
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors | 2007 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2008 |
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides | 2010 |
Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method.
Topics: Animals; Carbamates; Chromatography, Liquid; Drug Stability; Furans; Hydrophobic and Hydrophilic Interactions; Male; Mass Spectrometry; Organophosphates; Phosphates; Prodrugs; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2010 |
In-vitro dynamic dissolution/bioconversion/permeation of fosamprenavir using a novel tool with an artificial biomimetic permeation barrier and microdialysis-sampling.
Topics: Alkaline Phosphatase; Animals; Biomimetics; Cattle; Esters; Humans; Microdialysis; Organophosphates; Phosphates; Prodrugs; Solubility | 2023 |
The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
Topics: Animals; Enzyme Inhibitors; Esophageal Neoplasms; Laryngopharyngeal Reflux; Mice; Pepsin A; Protease Inhibitors; Proton Pump Inhibitors; Quality of Life | 2023 |